Aim of this paper is to provide a brief introduction on the biomaterials used in urology, discussing issues of biocompatibility and biomaterials available for use. Information will moreover be provided on basic elements of Tissue engineering and Regenerative medicine, rapidly advancing technologies that could finally shift in the next future from the laboratory to clinical practice, with special interest to possible urological applications.
DenstedtJ.D., WollinT.A., ReidG.Biomaterials Used in Urology: Current Issues of Biocompatibility, Infection, and Encrustation. J Endourol1998; 12(6): 493–500.
2.
ReidG., MillsapK., DenstedtJ.Biomaterials in Urology II: Future Usage and Management. J Endourol1999; 13(1): 1–7.
3.
DesgrandchampsF.Biomaterials in functional reconstruction. Curr Opin Urol2000; 10: 201–206.
4.
WoodaD., SouthgatebJ.Current status of tissue engineering in urology. Curr Opin Urol2008; 18: 564–569.
5.
WezelF., SouthgateJ., ThomasD.F.Regenerative medicine in urology. BJU Int2011; 108(7): 1046–1065.
6.
National Institutes of Health (NIH).Clinical applications of biomaterials. NIH Consensus Statement1982; 4(5): 1–19.
NaceyJ.N., HorsfallD.J., DelahuntB.. The assessment of urinary catheter toxicity using cell cultures: validation by comparison with an animal model. J Urol1986; 136: 706–709.
16.
RatnerB.D.Characterization of graft polymers for biomedical applications. J Biomed Mater Res1980; 14: 665–687.
17.
MarxM., BettmannM.A., BridgeS., BrodskyG., BoxtL.M., RichieJ.P.The effects of various indwelling ureteral catheter materials on the normal canine ureter. J Urol1984; 139: 180–184.
18.
CormioL., TaljaM., KoivusaloA.. Biocompatibility of various indwelling double-J stents. J Urol1995; 153: 494–496.
19.
BitschaiJ., BrodnyM.L.A History of Urology in Egypt.New York: Riverside Press1956: 76.
RuutuM., AlfthanO., HeikkinenL.. Epidemic of acute urethral stricture after open-heart surgery. Lancet1982; 1: 18.
22.
FerrieB.G., GreeneJ., SethiaB.. Comparison of silicone and latex catheters in the development of urethral stricture after cardiac surgery. Br J Urol1986; 58: 549–550.
23.
NaceyJ.N., DelahuntB.Urinary catheter toxicity. N Z Med J1991; 104: 355–356.
24.
SaltzmannB.Ureteral stents: indications, variations, and complications. Urol Clin North Am1988; 15: 481–491.
25.
CompanV., San RomanJ., RiandeE., SorensenT.S., LevenfeldB., AndrioA.Oxygen transport through methacrylate-based hydrogels with potential biological capability. Biomaterials1996; 17: 1243–1249.
KulikE., IkadaY.In vitro platelet adhesion to nonionic and ionic hydrogels with different water contents. J Biomed Mater Res1996; 30: 295–304.
28.
DuncanA.C., SeftonM.V., BrashJ.L.Preparation and characterization of alkylated polyvinyl alcohol hydrogels using alkyl halides. J Biomater Sci Polymer Ed1996; 7: 647–659.
29.
KurisawaM., TeranoM., YuiN.Double-stimuli-responsive degradation of hydrogels consisting of oligopeptide-terminated polyethylene glycol and dextran with an interpenetrating polymer network. J Biomater Sci Polymer Ed1997; 8: 691–708.
30.
D'UrsoE.M., Jean-FrancoisJ., DoillonC.J., FortierG.Polyethylene glycol-serum albumin hydrogel as matrix for enzyme immobilization: biomédical applications. Artif Cells Blood Subst Immobil Biotechnol1995; 23: 587–595.
31.
CandelaJ.V., BellmanG.C.Ureteral stents: impact of diameter and composition on patient symptoms. J Endourol1997; 11: 45–47.
32.
CoxA.J., HukinsD.W.L., SuttonT.M.Comparison of in vitro encrustation on silicone and hydrogel-coated latex catheters. Br J Urol1988; 61: 156–161.
33.
CoxA.J., MillingtonR.S., HukinsD.W., SuttonT.M.Resistance of catheters coated with a modified hydrogel to encrustation during an in vitro test. Urol Res1989; 17: 353–356.
34.
WezelF., SouthgateJ., ThomasD.F.Regenerative medicine in urology. BJU Int2011; 108(7): 1046–1065.
35.
HarousseauJ.L.Role of stem cell transplantation. Hematol Oncol Clin North Am2007; 21: 1157–1174.
36.
ThomsonJ.A., Itskovitz-EldorJ., ShapiroS.S.. Embryonic stem cell lines derived from human blastocysts. Science1998; 282: 1145–1147.
37.
WilmutI., SchniekeA.E., McWhirJ., KindA.J., CampbellK.H.Viable offspring derived from fetal and adult mammalian cells. Nature1997; 385: 810–813.
38.
HochedlingerK., RideoutW.M., KybaM., DaleyG.Q., BlellochR., JaenischR.Nuclear transplantation, embryonic stem cells and the potential for cell therapy. Hematol J2004; 5(Suppl. 3): S114–117.
39.
TakahashiK., YamanakaS.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006; 126: 663–676.
40.
De CoppiP., BartschG.Jr., SiddiquiM.M.. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol2007; 25: 100–106.
41.
PiscagliaA.C., NoviM., CampanaleM., GasbarriniA.Stem cell-based therapy in gastroenterology and hepatology. Minim Invasive Ther Allied Technol2008; 17: 100–118.
42.
LarsenW.J.Essentials of Human Embryology.New York: Churchill Livingstone1998.
43.
RossantJ.Stem cells and early lineage development. Cell2008; 132: 527–531.
44.
LambaD.A., GustJ., RehT.A.Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell2009; 4: 73–79.
CloutierF., SiegenthalerM.M., NistorG., KeirsteadH.S.Transplantation of human embryonic stem cell-derived oligodendrocyte progenitors into rat spinal cord injuries does not cause harm. Regen Med2006; 1: 469–479.
47.
AasenT., RayaA., BarreroM.J.. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol2008; 26: 1276–1284.
48.
UtikalJ., MaheraliN., KulalertW., HochedlingerK.Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci2009; 122: 3502–3510.
49.
TsaiS.Y., ClavelC., KimS.. Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells2010; 28: 221–228.
50.
MaheraliN., SridharanR., XieW.. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell2007; 1: 55–70.
51.
KnoepflerP.S.Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells2009; 27: 1050–1056.
WiesmannH.P., MeyerU.Biomaterials. In Meyer U, Meyer T, Handschel J, Wiesmann HP eds. Fundamentals of Tissue Engineering and Regenerative Medicine. Springer-Verlag, Berlin Heidelberg2009; 34: 457–468.
54.
WiesmannH.P., LammersL.Scaffold structure and fabrication. In Meyer U, Meyer T, Handschel J, Wiesmann HP eds. Fundamentals of Tissue Engineering and Regenerative Medicine. SpringerVerlag, Berlin Heidelberg2009; 39: 539–550.
55.
StenzlA., CowanN.C., De SantisM.. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol2009; 55: 815–825.
JemalA., SiegelR., WardE., HaoY., XuJ., ThunM.J.Cancer statistics, 2009. CA Cancer J Clin2009; 59: 225–249.
58.
TumlinJ., WaliR., WilliamsW.. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol2008; 19: 1034–1040.
59.
HumesH.D., WeitzelW.F., BartlettR.H.. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int2004; 66: 1578–1588.
60.
SongJ.H., HumesH.D.Renal cell therapy and beyond. Semin Dial2009; 22: 603–609.
61.
FeldmanH.A., GoldsteinI., HatzichristouD.G., KraneR.J., McKinlayJ.B.Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol1994; 151: 54–61.
LysaghtM.J., JaklenecA., DeweerdE.Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng Part A2008; 14: 305–315.
64.
WoodD., SouthgateJ.Current status of tissue engineering in urology. Curr Opin Urol2008; 18: 564–569.
65.
McAteerH., CoshE., FreemanG., PanditA., WoodP., LilfordR.Cost-effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra. J Tissue Eng Regen Med2007; 1: 343–349.
